Canadian physicians and medical regulators continue to need guidance regarding opioid use for chronic non-cancer pain.
In 2010, the National Opioid Use Guideline Group offered recommendations for safe and effective use of opioids. Despite the implementation of the guidelines being associated with a decline in opioid use, critics characterized the recommendations as containing little direction about when not to prescribe or when to limit doses or duration of therapy.
The 2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain attempts to address these concerns by adhering to current best practices for systematic reviews and guideline development and incorporating evidence published since that used to inform the 2010 guideline. The 2017 guideline provides strong or weak recommendations when evidence is consistent, and best practice statements and expert guidance when evidence is conflicting or absent.
The recommendations in the 2017 Canadian Guideline will assist physicians and other health care providers to use opioids effectively and safely in patients with chronic non-cancer pain. The best practice and expert guidance statements will also help physicians inform patients about the potential benefits and risks of opioids, and enable other healthcare providers to be aware of roles they can play to achieve desired patient outcomes.
This module explores the 2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain through case presentations and summaries, and includes many useful tools to help manage, assess and monitor patients using opioid therapy for chronic non-cancer pain.
After completing this course, you will be able to:
Funds in support of this CPD activity were provided as an educational grant to Memorial University and independently allocated and disbursed in accordance with current CMA guidelines. Funds in support of this program were provided by McMaster University through a grant from Health Canada.